Inhibikase Therapeutics (IKT) Shares Outstanding (2020 - 2026)

Inhibikase Therapeutics (IKT) has reported Shares Outstanding (Entity) for 7 consecutive years, with $172.3 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Shares Outstanding (Entity) rose 131.78% year-over-year to $172.3 million; the TTM figure through Mar 2026 stood at $172.3 million (up 131.78% YoY), while the FY2025 annual figure was $98.3 million, up 314.6% from the prior year.
• Shares Outstanding (Entity) grew to $172.3 million in Q1 2026 per IKT's latest filing, from $98.3 million in the prior quarter.
• Across five years, Shares Outstanding (Entity) topped out at $172.3 million in Q1 2026 and bottomed at $4.2 million in Q1 2022.
• Historically, Shares Outstanding (Entity) has averaged $34.0 million across 5 years, with a median of $6.5 million in 2024.
• Annual changes were most pronounced in 2022 — Shares Outstanding (Entity) gained 0.29% — and 2025, when it surged 1047.81%.
• Inhibikase Therapeutics' Shares Outstanding (Entity) stood at $4.2 million in 2022, then surged by 47.13% to $6.2 million in 2023, then surged by 283.3% to $23.7 million in 2024, then jumped by 314.6% to $98.3 million in 2025, then soared by 75.27% to $172.3 million in 2026.
• Business Quant data shows IKT's Shares Outstanding (Entity) at $172.3 million in Q1 2026, $98.3 million in Q4 2025, and $74.8 million in Q3 2025.